BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO)
Provided By GlobeNewswire
Last update: Jul 3, 2025
Adverse events were generally low-grade, transient, and readily manageable
Achieved preliminary evidence of prolonged tumor control and tumor reductions in heavily pretreated adenocarcinoma patients
Read more at globenewswire.com0.76
+0.04 (+5.56%)
Find more stocks in the Stock Screener
BCAB Latest News and Analysis
